Trial Profile
Maintained Capacity to Respond to Micro-environmental Stimuli through the Toll-like Receptors in patients with chronic lymphocytic leukaemia recieving ibrutinib as first-line or subsequent therapies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2017
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 07 Apr 2017 New trial record